# D3 Bio (Wuxi)

Source: https://onco.cc/companies/d3-bio-wuxi/  
OnCo record `d3-bio-wuxi` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

D3 Bio (Wuxi) is a China-based biotechnology company running 2 late-stage cancer trials.

## Summary

D3 Bio (Wuxi), based in Wuxi, China, is a biotechnology company. D3 Bio is a private, clinical-stage biotechnology company developing precision oncology and immunology medicines targeting immune pathways and tumour-driving mutations. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials. The largest, NCT05410145 (A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumours With a KRAS p.G12C Mutation), plans to enrol 442 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website. Its website describes D3S-001 as a next-generation KRAS G12C-selective inhibitor for non-small-cell lung and colorectal cancers with that mutation, and D3S-003 as a KRAS G12D inhibitor.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: D3 Bio (Wuxi) Co., Ltd
- Tags: ctgov-sponsor
- HQ: Wuxi
- Type: biotech
- Website: https://www.d3bio.com

## Sources

- Official website: https://www.d3bio.com
- ClinicalTrials.gov: trials led by D3 Bio (Wuxi): https://clinicaltrials.gov/search?lead=D3%20Bio%20(Wuxi)%20Co.%2C%20Ltd
- D3 Bio pipeline: https://www.d3bio.com/

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [KRAS & RAS inhibitors](https://onco.cc/technologies/kras-inhibitors/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)
- trials: [A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations](https://onco.cc/trials/nct05886920/), [A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation](https://onco.cc/trials/nct05410145/)

---
JSON: https://onco.cc/api/v1/entities/d3-bio-wuxi.json